Table of Content

           
Table of Contents
 
1. Introduction to Bispecific Antibody
  1.1 Overview
  1.2 Clinical Advancement of Bispecific Antibodies
 
2. Bispecific Antibodies Combination Strategies
  2.1 Chemotherapies
  2.2 Targeted Therapies
  2.3 Immunotherapies
  2.4 Radiotherapy
 
3. Commercially Approved Bispecific Antibodies Insight
  3.1 Company, Indication, Location & MOA
  3.2 Bispecific Antibodies Granted FDA & EMA Designations
 
4. Bispecific Antibodies Proprietary Platforms
 
5. Global & Regional Bispecific Antibody Market Outlook
  5.1 Yearly & Quarterly Sales Insight (2019 to 2023)
  5.2 Approved Bispecific Antibodies Reimbursement Policy
  5.3 Global Bispecific Antibody Market Forecast 2029
 
6. Global Bispecific Antibody Market Trends By Region
  6.1 US
  6.2 Europe
  6.3 China
  6.4 UK
  6.5 Japan
  6.6 South Korea
  6.7 Australia
  6.8 Canada
  6.9 Latin America
 
 
7. Global Bispecific Antibodies Research & Market Trends by Indications
  7.1 Lymphoma
  7.2 Multiple Myeloma
  7.3 Leukemia
  7.4 Lung Cancer
  7.5 Melanoma
  7.6 Blood Disorders
  7.7 Gastrointestinal Cancers
  7.8 Other Cancers
  7.9 Autoimmune & Inflammatory Diseases
  7.10 Microbial Diseases
  7.11 Ocular Diseases
 
8. Global Bispecific Antibodies Clinical Trials Overview
  8.1 By Phase
  8.2 By Country/Region
  8.3 By Company
  8.4 By Indication
  8.5 By Priority Status
  8.6 Patient Segment
 
9. Blincyto – Clinical, Patent, Pricing & Sales Insight
  9.1 Overview & Patent Insight
  9.2 Pricing & Dosage Analysis
  9.3 Sales Analysis
 
10. Hemlibra - Clinical, Patent, Pricing & Sales Insight
  10.1 Overview
  10.2 Pricing & Dosage Insight
  10.3 Sales Analysis

 
11. Rybrevant - Clinical, Patent & Pricing Insight
  11.1 Overview
  11.2 Pricing & Dosage Insight
 
12. Kimmtrak - Clinical, Patent, Pricing & Sales Insight
  12.1 Overview
  12.2 Pricing & Dosage Insight
  12.3 Sales Analysis
 
13. Vabysmo - Clinical, Patent, Pricing & Sales Insight
  13.1 Overview
  13.2 Pricing & Dosage Insight
  13.3 Sales Analysis
 
14. Lunsumio - Clinical, Patent, Pricing & Sales Insight
  14.1 Overview & Patent Insight
  14.2 Pricing & Dosage Insight
  14.3 Sales Analysis
 
15. Cadonilimab – Clinical & Sales Insight
 
16. Tecvayli - Clinical, Patent & Pricing Insight
  16.1 Overview & Patent Insight
  16.2 Pricing & Dosage Insight
 
17. Columvi - Clinical, Patent, Pricing & Sales Insight
  17.1 Overview & Patent Insight
  17.2 Pricing & Dosage Insight
  17.3 Sales Analysis
 
18. Epkinly - Clinical, Patent, Pricing & Sales Insight
  18.1 Overview
  18.2 Pricing & Dosage Insight
  18.3 Sales Analysis

 
19. Talvey - Clinical, Patent & Pricing Insight
  19.1 Overview & Patent Insight
  19.2 Pricing & Dosage Insight
 
20. Elrexfio - Clinical, Patent & Pricing Insight
  20.1 Overview
  20.2 Pricing & Dosage Insight
 
21. Global Bispecific Antibodies Clinical Trials By Company, Indication & Phase
  21.1 Research
  21.2 Preclinical
  21.3 Phase-I
  21.4 Phase-I/II
  21.5 Phase-II
  21.6 Phase-II/III
  21.7 Phase-III
  21.8 Preregistration
  21.9 Registered
 
22. Marketed Bispecific Antibodies Clinical Insight By Company, Country & Indication
 
23. Competitive Landscape
  23.1 ABL Bio
  23.2 Abzyme Therapeutics
  23.3 Affimed Therapeutics
  23.4 Akeso Biopharma
  23.5 Alligator Bioscience
  23.6 Amgen
  23.7 Antibody Therapeutics
  23.8 APITBIO
  23.9 Aptevo Therapeutics
  23.10 Astellas Pharma
  23.11 AstraZeneca
  23.12 BioAtla
  23.13 Biosion
  23.14 Biotheus
  23.15 BJ Bioscience
  23.16 EpimAb Biotherapeutics
  23.17 FutureGen Biopharmaceutical
  23.18 Genentech
  23.19 Genmab
  23.20 Gensun Biopharma
  23.21 Harbour BioMed
  23.22 IGM Biosciences
  23.23 I-MAB Biopharma
  23.24 ImmuneOnco Biopharma
  23.25 ImmunoPrecise Antibodies
  23.26 Innovent Biologics
  23.27 Invenra
  23.28 Janssen Research & Development
  23.29 Kenjockety Biotechnology
  23.30 LaNova Medicines Limited
  23.31 Light Chain Bioscience
  23.32 Linton Pharm
  23.33 Lyvgen Biopharma
  23.34 MacroGenics
  23.35 Merus
  23.36 NovaRock Biotherapeutics
  23.37 Pfizer
  23.38 Phanes Therapeutics
  23.39 Prestige BioPharma
  23.40 Regeneron Pharmaceuticals
  23.41 Revitope
  23.42 Roche
  23.43 Virtuoso Therapeutics
  23.44 Xencor
  23.45 Y-Biologics
  23.46 Zhejiang Shimai Pharmaceutical
  23.47 Zymeworks 
 
List of Figures
 
Figure 1-1: Bispecific Antibodies - Advantages
 
Figure 2-1: Antibody-Chemotherapy Combination - Advantages
Figure 2-2: Antibody-Chemotherapy Combination – Impending Challenges
 
Figure 3-1: Blincyto - Mechanism of Action
Figure 3-2: Hemlibra - Mechanism of Action
Figure 3-3: Rybrevant - Mechanism of Action
Figure 3-4: Regulatory Designations - Benefits
 
Figure 4-1: Multiclonics - Distinctive Characteristics
Figure 4-2: Biclonics - Format
Figure 4-3: ADAPTIR Bispecific Structure
Figure 4-4: ADAPTIR-FLEX
Figure 4-5: BEAT Platform - Multispecific Antibodies
Figure 4-6: FIT-Ig - Proprietary Bispecific Platform
Figure 4-7: BiClone format
Figure 4-8: BioAtla CABs – Features
Figure 4-9: BioAtla CABs – Benefits
Figure 4-10: IMBiologic Bispecific Antibodies - Strategy
Figure 4-11: IMBiologic Bispecific Antibodies – Mechanism of Action
Figure 4-12: Novel HBICE
Figure 4-13: HBICE - Mechanism of Action 1
Figure 4-14: HBICE - Mechanism of Action 2
Figure 4-15: Phanes Therapeutics – PACbody Platform
Figure 4-16: Phanes Therapeutics – SPECpair Platform
Figure 4-17: Phanes Therapeutics – ATACCbody
Figure 4-18: Numab Therapeutics - Technology
Figure 4-19: Grabody I Platform - Mechanism of Action
Figure 4-20: Grabody I Platform - Mechanism of Action
Figure 4-21: 3-Step DuoBody Production Process
Figure 4-22: DuoHexaBody Molecules – Schematic
Figure 4-23: iTAb – Patented Structure
Figure 4-24: iTAb – Mechanism of Action
Figure 4-25: Synimmune - Proprietary Bispecific Antibody Format
Figure 4-26: BiTE - Structure
Figure 4-27: BiTE Molecule
Figure 4-28: Sanyou Super Trillion Common Light Chain Antibody Discovery Platform
Figure 4-29: ALiCE – Characteristics
Figure 4-30: ALiCE - Schematic Diagram & Mechanism of Action
Figure 4-31: Abz2 Bispecific Platform
Figure 4-32: Abz2 Bispecifics - Benefits
Figure 4-33: Neo-X-Prime Bispecific Mechanism
Figure 4-34: B-Body Bispecific Antibody - Structre
Figure 4-35: xLinkBsAb - Structure
Figure 4-36: PrecisionGATE Bispecific Antibody – Structure
 
Figure 5-1: Global – Annual Bispecific Antibody Market (US$ Million), 2019-2023
Figure 5-2: Global – Quarterly Bispecific Antibody Market (US$ Million), 2023
Figure 5-3: Global - Annual Bispecific Antibodies Market by Drug (US$ Million), 2023
Figure 5-4: Global - Bispecific Antibodies Market Shares by Drugs (%), 2023
Figure 5-5: Global - Annual Bispecific Antibody Market by Region (US$ Billion), 2023
Figure 5-6: Global – Bispecific Antibody Market Shares by Region (%), 2023
Figure 5-7: Global – Annual Bispecific Antibodies Sales by Drugs (US$ Million), 2022
Figure 5-8: Global - Bispecific Antibodies Market Shares by Drugs (%), 2022
Figure 5-9: Global - Bispecific Antibody Market by Region (US$ Million), 2022
Figure 5-10: Global - Bispecific Antibody Market Shares by Region (%), 2022
Figure 5-11: US – Annual Bispecific Antibody Market Value (US$ Million), 2019-2023
Figure 5-12: ROW – Global Bispecific Antibody Market Value (US$ Million), 2019-2023
Figure 5-13: US - Quarterly Bispecific Antibodies Market (US$ Million), 2023
Figure 5-14: ROW - Quarterly Bispecific Antibodies Market (US$ Million), 2023
Figure 5-15: Blincyto - Total Treatment Cost & Reimbursement Cost
Figure 5-16: Blincyto – In Pocket & Out of Pocket Cost of Treatment
Figure 5-17: Hemlibra - Total Treatment Cost & Reimbursement Cost
Figure 5-18: Hemlibra – In Pocket & Out of Pocket Cost of Treatment
Figure 5-19: Rybrevant - Maximum Coverage by Medicaid (US$), 2023
Figure 5-20: Rybrevant - Maximum Coverage by Private Insurance Coverage (US$), 2021
Figure 5-21: Vabysmo - Total Treatment Cost & Reimbursement Cost
Figure 5-22: Vabysmo – In Pocket & Out of Pocket Cost of Treatment
Figure 5-23: Global - Bispecific Antibody Market Opportunity Assessment (US$ Billion), 2024 – 2029
 
Figure 6-1: US – Bispecific Antibodies Approval
Figure 6-2: Blincyto - US v/s ROW Sales (US$ Million), 2023
Figure 6-3: Blincyto - US v/s ROW Shares (%), 2023
Figure 6-4: Blincyto - US v/s ROW Sales (US$ Million), 2022
Figure 6-5: Blincyto - US v/s ROW Shares (%), 2022
Figure 6-6: Hemlibra - US v/s ROW Sales (US$ Million), 2023
Figure 6-7: Hemlibra – US v/s ROW Shares (%), 2023
Figure 6-8: Hemlibra - US v/s ROW Sales (US$ Million), 2022
Figure 6-9: Hemlibra - US v/s ROW Shares (%), 2022
Figure 6-10: Global – US v/s ROW in Bispecific Antibodies Market (US$ Million), 2023
Figure 6-11: Global – US v/s ROW Shares in Bispecific Antibodies Market (%), 2023
Figure 6-12: Global – US v/s ROW in Bispecific Antibodies Market (US$ Million), 2022
Figure 6-13: Global – US v/s ROW Shares in Bispecific Antibodies Market (%), 2022
Figure 6-14: Blincyto – US Patent Filing & Expiration Year
Figure 6-15: Blincyto – EU Patent Expiration
Figure 6-16: Vabysmo – Canada Patent Numbers Expiration & Approval Year
Figure 6-17: Hemlibra – Canada Patent Numbers Approval & Expiration Year
Figure 6-18: Rybrevant – Canada Patent Numbers Approval & Expiration Year
Figure 6-19: Kimmtrak – Canada Patent Number Approval & Expiration Year
 
Figure 7-1: Bispecific Antibodies - Advantages
Figure 7-2: TG-1801 Phase 1 Study – Initiation & Completion Year
Figure 7-3: Bispecific Antibodies – Future Opportunities
Figure 7-4: Mim8 Phase 3 (NCT05053139) Study – Initiation & Completion Year
Figure 7-5: Mim8 Phase 3 (NCT05878938) Study – Initiation & Completion Year
Figure 7-6: NXT007 Phase 1/2 (NCT05987449) Study – Initiation & Completion Year
Figure 7-7: HMB-001 Phase 1/2 (NCT06211634) Study – Initiation & Completion Year
Figure 7-8: REGN4018 Phase 1/2 (NCT03564340) Study – Initiation & Completion Year
Figure 7-9: PRV-3279 Phase 2 (NCT05087628) Study – Initiation & Completion Year
 
Figure 8-1: Global - Bispecific Antibodies Clinical Pipeline by Phase (Numbers), 2023
Figure 8-2: Global - Bispecific Antibodies in Clinical Pipeline by Country (Numbers), 2024 till 2029
Figure 8-3: Global - Bispecific Antibodies in Clinical Pipeline by Company (Numbers), 2024 till 2029
Figure 8-4: Global - Bispecific Antibodies in Clinical Pipeline by Indication (Numbers), 2023 till 2029
Figure 8-5: Global - Bispecific Antibodies in Clinical Pipeline by Orphan Status (Numbers), 2023 till 2029
Figure 8-6: Global - Bispecific Antibodies in Clinical Pipeline by Patient Segment (Numbers), 2023 till 2029
 
Figure 9-1: Blincyto – Approval Year by Region
Figure 9-2: Blincyto – Patent Filing & Expiration Year
Figure 9-3: Blincyto - Treatment Regimen Cycles (Weeks)
Figure 9-4: Blincyto – Duration of Treatment Phase & Resting Phase in Induction & Consolidation Cycles for Treatment of MRD-Positive B-cell precursor (Days)
Figure 9-5: Blincyto - Cost of Single Cycle & Treatment Course for the Treatment of MRD-positive B-cell Precursor ALL
Figure 9-6: Blincyto – Recommended Number of Induction & Consolidation Treatment Cycle for Relapsed B-Cell Precursor ALL
Figure 9-7: Blincyto – Duration of Single Induction, Consolidation, Continued Cycle & Full Treatment for Relapsed B-Cell Precursor ALL (Weeks)
Figure 9-8: Blincyto - Cost of Single Cycle & Treatment Course for Treatment for Relapsed B-Cell Precursor ALL
Figure 9-9: Global – Blincyto Sales (US$ Million), 2019–2023
Figure 9-10: Global – Blincyto Sales (US$ Million), Q1 – Q4’2023
Figure 9-11: Blincyto - US v/s ROW Sales (US$ Million), 2023
Figure 9-12: Global – Blincyto Sales by Region (%), 2023
Figure 9-13: US – Blincyto Sales (US$ Million), Q1 – Q4’2023
Figure 9-14: ROW – Blincyto Sales (US$ Million), Q1 – Q4’2023
Figure 9-15: US – Blincyto Sales ((US$ Million), 2019-2023
Figure 9-16: ROW – Blincyto Sales (US$ Million), 2019-2023
 
Figure 10-1: Hemlibra – Approval Years by Region
Figure 10-2: Hemlibra – Cost per Unit & Supply of 150 mg/mL Subcutaneous Injection (US$), February’2024
Figure 10-3: Hemlibra – Recommended Loading & Maintenance Dose for Treatment of Hemophilia (mg/kg/Week)
Figure 10-4: Global – Hemlibra Sales (US$ Million), 2019-2023
Figure 10-5: US – Hemlibra Sales (US$ Million), 2019-2023
Figure 10-6: Europe – Hemlibra Sales (US$ Million), 2019-2023
Figure 10-7: Japan – Hemlibra Sales (US$ Million), 2019-2023
Figure 10-8: ROW – Hemlibra Sales (US$ Million), 2019-2023
Figure 10-9: Global – US v/s ROW Sales (US$ Million), 2023
Figure 10-10: Global – Hemlibra Annual Sales by Region (US$ Million), 2023
Figure 10-11: Global – Hemlibra Sales by Region (%), 2023
Figure 10-12: Global – Hemlibra Sales (US$ Million), Q1 – Q4’2023
Figure 10-13: US – Hemlibra Sales (US$ Million), Q1 – Q4’2023
Figure 10-14: Europe – Hemlibra Sales (US$ Million), Q1 – Q4’2023
Figure 10-15: Japan – Hemlibra Sales (US$ Million), Q1 – Q4’2023
Figure 10-16: ROW – Hemlibra Sales (US$/ US$ Million), Q1 – Q4’2023
 
Figure 11-1: Rybrevant – Price per Unit & Supply of Intravenous Solution (US$), February’2024
Figure 11-2: Rybrevant – Recommended Dose Per Cycle by Body Weight (mg)
Figure 11-3: Rybrevant – Dose Reduction in Patients with Weight less than 80 kg (mg)
Figure 11-4: Rybrevant – Dose Reduction in Patients with Weight more than 80 Kg (mg)
 
Figure 12-1: Kimmtrak – Approval Year by Region
Figure 12-2: Kimmtrak – Cost Per Unit & Per Vial (US$), February’2024
Figure 12-3: Global – Annual Kimmtrak Sales (US$ Million), 2021-2023
Figure 12-4: Global – Quarterly Kimmtrak Sales (US$ Million), 2023
Figure 12-5: Kimmtrak – Sales by Region (US$ Million), 2023
Figure 12-6: Kimmtrak – US v/s ROW Market Shares (US$ Million), 2023
Figure 12-7: Kimmtrak – US v/s ROW Market Shares (%), 2023
Figure 12-8: US – Quarterly Kimmtrak Sales (US$ Million), 2023
Figure 12-9: EU – Quarterly Kimmtrak Sales (US$ Million), 2023
Figure 12-10 ROW – Quarterly Kimmtrak Sales (US$ Million), 2023
 
Figure 13-1: Vabysmo – Approval Year by Region
Figure 13-2: Vabysmo – Price per Unit & Supply of Intravitreal Solution (US$), February’2024
Figure 13-3: Global – Vabysmo Sales (US$ Million), 2022-2023
Figure 13-4: Global – Vabysmo US v/s ROW Sales (US$ Million), 2023
Figure 13-5: Global – Vabysmo Annual Sales by Region (US$ Million), 2023
Figure 13-6: Global – Vabysmo Annual Sales by Region (%), 2023
Figure 13-7: US – Vabysmo Sales (US$ Million), 2022-2023
Figure 13-8: Europe – Vabysmo Sales (US$ Million), 2022-2023
Figure 13-9: Japan – Vabysmo Sales (US$ Million), 2022-2023
Figure 13-10: ROW – Vabysmo Sales (US$ Million), 2022-2023
Figure 13-11: Global – Vabysmo Sales (US$ Million), Q1 – Q4’2023
Figure 13-12: US – Vabysmo Sales (US$ Million), Q1 – Q4’2023
Figure 13-13: Europe – Vabysmo Sales (US$ Million), Q1 – Q4’2023
Figure 13-14: Japan – Vabysmo Sales (US$ Million), Q1 – Q4’2023
Figure 13-15: ROW – Vabysmo Sales (US$ Million), Q1 – Q4’2023
 
Figure 14-1: Lunsumio – Approval Years by Region
Figure 14-2: US – Price per Unit & Supply of Lunsumio Intravenous Solution (US$), February’2024
Figure 14-3: EU – Price per Unit & Supply of Lunsumio Intravenous Solution (US$), February’2024
Figure 14-4: Global – Lunsumio Sales (US$ Million), 2022-2023
Figure 14-5: US – Lunsumio Sales (US$ Million), 2022-2023
Figure 14-6: Europe – Lunsumio Sales (US$ Million), 2022-2023
Figure 14-7: Global – Lunsumio Annual Sales by Region (US$ Million), 2023
Figure 14-8: Global – Lunsumio Annual Sales by Region (%), 2023
Figure 14-9:– Global - Lunsumio Sales (US$ Million), Q1 – Q4’2023
Figure 14-10: US – Lunsumio Sales (US$ Million), Q1 – Q4’2023
Figure 14-11: Europe – Lunsumio Sales (US$ Million), Q1 – Q4’2023
 
Figure 15-1: Annual – Cadonilimab Sales (US$ Million), H2’2022 & H1’2023
 
Figure 16-1: Tecvayli – Approval Years by Region
Figure 16-2: Tecvayli – Patent Acceptance & Expiration Years
Figure 16-3: US – Cost per Unit & Supply of Tecvayli Subcutaneous Solution (US$), February’2024
Figure 16-4: EU - Cost per Unit & Supply of Tecvayli Subcutaneous Solution (US$), February’2024

 
Figure 17-1: Columvi – Approval Year by Region
Figure 17-2: US – Price per Unit & Supply of Columvi Intravenous Solution (US$), February’2024
Figure 17-3: EU – Price per Unit & Supply of Columvi Intravenous Solution (US$), February’2024
Figure 17-4: Global – Columvi Sales by Region (US$ Million), 2023
Figure 17-5: Global – Columvi Sales (US$ Million), Q1 – Q4’2023
Figure 17-6: US – Columvi Sales (US$ Million), Q1 – Q4’2023
Figure 17-7: Europe – Columvi Sales (US$ Million), Q1 – Q4’2023
 
Figure 18-1: Epkinly – Approval Year by Region
Figure 18-2: US - Cost per Unit & Supply of Epkinly Subcutaneous Solution (US$), February’2024
Figure 18-3: EU - Cost per Unit & Supply of Epkinly Subcutaneous Solution (US$), February’2024
Figure 18-4: Global – Epkinly Sales (US$ Million), 2023
Figure 18-5: Global – Epkinly Sales (US$ Million), Q1 – Q4’2023
 
Figure 19-1: Talvey – Approval Year by Region
Figure 19-2: Talquetamab – FDA & EMA Designation Year
Figure 19-3: Talvey – Patent Acceptance & Expiration Year
Figure 19-4: US – Price per Unit & Supply of Talvey Intravenous Solution (US$), February’2024
Figure 19-5: EU – Price per Unit & Supply of Talvey Intravenous Solution (US$), February’2024
 
Figure 20-1: Elrexfio – Approval Years by Region
Figure 20-2: Elranatamab – FDA & EMA Designation Years
Figure 20-3: US – Price per Unit & Supply of Elrexfio Subcutaneous Solution (US$), February’2024
 

 
 
List of Tables
 
Table 2-1: Bispecific Antibody & Chemotherapy Combinations in Clinical Trials
Table 2-2: Bispecific Antibody & Targeted Therapy Combinations in Clinical Trials
Table 2-3: Bispecific Antibody & Immunotherapy Combinations in Clinical Trials
Table 2-4: Bispecific Antibody & Radiotherapy Combinations in Clinical Trials
 
Table 3-1: Approved Bispecific Antibodies
Table 3-2: US - Bispecific Antibodies with Regulatory Designations
Table 3-3: EU - Bispecific Antibodies with Regulatory Designations
Table 3-4: EU - Bispecific Antibodies with Regulatory Designations
 
Table 5-1: Epkinly - Billing Unit Application for Doses
Table 5-2: Talvey - Coverage Summary
Table 5-3: Talvey - Coding Summary
Table 5-4: Elrexfio - HCPCS Codes
Table 5-5: Elrexfio - HCPCS modifiers
 
Table 6-1: US – FDA IND Applications Accepted, February’2024
Table 6-2: EU - Bispecific Antibodies in Late Stage Clinical Trials
Table 6-3: Bispecific Antibodies in Clinical Trials in Latin America
 
Table 7-1: Lymphoma - Bispecific Antibodies in Clinical Trials
Table 7-2: Multiple Myeloma - Bispecific Antibodies in Clinical Trials
Table 7-3: Leukemia - Bispecific Antibodies in Clinical Trials
Table 7-4: Lung Cancer - Bispecific Antibodies in Clinical Trials
Table 7-5: Melanoma - Bispecific Antibodies in Clinical Trials
Table 7-6: Digestive System Cancers - Bispecific Antibodies in Clinical Trials
Table 7-7: Breast Cancer - Bispecific Antibodies in Clinical Trials
Table 7-8: Gynecological Cancers - Bispecific Antibodies in Clinical Trials
Table 7-9: Gynecological Cancers - Bispecific Antibodies in Clinical Trials
 
Table 9-1: Blincyto – Active Patents
Table 9-2: Blincyto - Recommended Dosage & Schedule for the Treatment of MRD-positive B-cell Precursor ALL
Table 9-3: Blincyto - Recommended Dosage & Schedule for Treatment of Relapsed or Refractory B-cell Precursor ALL
Table 9-4: Blincyto - Recommended Dosage & Schedule for Treatment of Relapsed or Refractory B-cell Precursor ALL
 
Table 11-1: Rybrevant – Premedication
Table 11-2: Rybrevant - Dose Reductions for Adverse Reactions
Table 11-3: Rybrevant - Recommended Dosage Modifications for Adverse Reactions
 
Table 12-1: Kimmtrak - Recommended Dosage for Treatment of Unresectable or Metastatic Uveal Melanoma
Table 12-2: Kimmtrak - Dose Modifications for Adverse Reactions
 
Table 14-1: Lunsumio – Recommended Treatment Cycles
Table 14-2: Lunsumio - Recommended Premedications
Table 14-3: Lunsumio - Recommendations for Management of Cytokine Release Syndrome
 
Table 16-1: Tecvayli - Dosing Schedule
Table 16-2: Tecvayli - Recommended Dosage Modifications for Adverse Reactions
 
Table 17-1: Columvi - Dosing Schedule (21-Day Treatment Cycles)
Table 17-2: Columvi - Premedications to be Administered
Table 17-3: Columvi - Recommendations for Management of Cytokine Release Syndrome
Table 17-4: Columvi - Recommended Dosage Modification for Neurologic Toxicity (Including ICANS)
Table 17-5: Columvi - Recommended Dosage Modifications for Other Adverse Reactions
 
Table 18-1: Epkinly - Dosage Schedule
Table 18-2: Epkinly - Recommendations for Management of Cytokine Release Syndrome
Table 18-3: Epkinly - Recommendations for Management of Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS)
Table 18-4: Epkinly - Recommended Dosage Modifications for Other Adverse Reactions
 
Table 19-1: Talvey - Weekly Dosing Schedule
Table 19-2: Talvey – Biweekly Dosing Schedule
Table 19-3: Talvey - Recommendations for Management of CRS
Table 19-4: Talvey - Recommendations for Management of Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS)
Table 19-5: Talvey - Recommendations for Management of Neurologic Toxicity (excluding ICANS)
Table 19-6: Talvey - Recommended Dosage Modifications for Other Adverse Reactions
 
Table 20-1: Elrexfio - Dosing Schedule
Table 20-2: Elrexfio – Recommendations for Management of CRS
Table 20-3: Elrexfio - Recommended Dosage Modifications for Other Adverse
Reactions